EF1a-hHOXA9(GFP, Puro) Lentiviral Particles

EF1α-hHOXA9(GFP, Puro) lentiviral particles are a cutting-edge tool for gene manipulation, with a robust EF1α promoter driving high-level, constitutive expression of human HOXA9 in a variety of cell types. This system combines the high efficiency of lentiviral transduction (capable of infecting both dividing and non-dividing cells and achieving stable genome integration) with dual-selection markers, enhancing experimental control. The integrated GFP reporter gene allows for real-time visualization and tracking of transduction efficiency and successful expression via fluorescence microscopy or flow cytometry, while the puromycin resistance gene enables rapid and cost-effective screening of stable transduced cell populations. The viral vector employs advanced safety design, including replication-deficient design, providing high functional titers suitable for both in vitro and in vivo applications while maintaining optimal biosafety standards.

This versatile lentiviral platform enables groundbreaking research in stem cell biology, regenerative medicine, and oncology. By promoting stable HOXA9 expression, this method efficiently immortalizes primary human cells, particularly hematopoietic progenitor cells, overcoming the limitations of traditional culture systems in long-term studies of differentiation and self-renewal mechanisms. Researchers used this tool to construct a leukemia model, investigate the role of HOXA9 in maintaining stem cell characteristics, and screen for hematopoietic regulatory factors. The GFP-purinemycin screening system significantly accelerated the construction of disease-related cell lines for drug development, while its constitutive expression profile allowed for time-series analysis of HOXA9-mediated transcriptional programs. Furthermore, this system is a key component in the development of synthetic gene circuits for cell therapy applications, where controlled HOXA9 expression holds promise for improving transplantation efficiency or modulating immune cell function in next-generation cancer immunotherapies.